Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee

March 4, 2003

 

Consultants (Voting)

Victor Santana, M.D., St. Jude Children’s Hospital

Alice Ettinger, R.N., Association of Pediatric Oncology Nurses

Jerry Finklestein, M.D., University of California, Los Angeles

Patrick C Reynolds, M.D., Los Angeles Children’s Hospital

James Boyett, Ph.D., St. Jude Children’s Hospital

Henry Friedman, M.D., Duke University

Susan Cohn, M.D., Northwestern University

Nancy Keene, Independent advocate (patient rep.)

Susan Weiner, Ph.D., Children’s Cause (patient rep.)

Oncologic Drugs Advisory Committee Members

Jody Pelusi, F.N.P., Ph.D., North Arizona Hematology & Oncology Associates

Gregory Reaman, M.D., Children’s Hospital National Medical Center, Washington, D.C.

 

 

Guest Speakers (Non-Voting)

Malcolm Smith, M.D., Cancer Treatment & Evaluation Program, National Cancer Institute, NIH

International Guests (Non-Voting)

Francesco Pignatti, M.D., European Medicinal Evaluation Agency (EMEA)

Katherine Cheng, M.D., Medicines Control Agency, UK

Anne Mathieu-Boue, M.D., Agence Francaise de Securite Sanitaires de Produits de Sante (AFSSAPS)

Gilles Vassal, M.D., AFSSAPS, Institut Gustave Roussy, France

Harald Schweim, M.D., Bundes Institut fur Arzneimittel und Medizinprodukte (Bfarm)

Mark Bernstein, M.D., Health Protection Branch, Canada

Industry Guests (Non-Voting)

Anne Hagey, M.D., Abbott Laboratories Global Oncology Development Group

Alan Melemed, M.D., Eli Lilly